acute myeloid leukemia Flashcards
midostaurin MOA/indications
indicated for newly diagnosed FLT-3 mutated AML in combination w/ standard cytarabine + daunorubicin (7+3) induction and cytarabine consolidation
gemtuzumab ozogamycin MOA/indications
Anti CD33 antibody-drug conjugate
indicated in adults with newly diagnosed CD33 positive AML and refractory or relapsed CD33 positive AML in patients over 2 years of age
CPX-351 MOA/indications
liposomal cytarabine and daunorubicin at 5:1 ratio
indicated for newly diagnosed therapy related AML, 2/2 AML or AML with MDS related changes
Glasdegib MOA/indications
hedgehog pathway inhibitor
indicated in newly diagnosed AML aged 75 or older unfit for intensive chemotherapy. used in combination with low dose cytarabine
venetoclax MOA/indications
BCL-2 inhibitor
indicated in combo w/ HMA in newly diagnosed AML in patient unable to undergo intensive chemotherapy induction
Enasidenib MOA/indications
IDH2 inhibitor
indicated in relapsed or refractory IDH2 mutated AML
Ivosidenib MOA/indications
IDH1 inhibitor
indicated as first line in IDH 1 mutated AML patients unable to receive induction intensive chemotherapy. also indicated as a salvage therapy in relapsed and refractory IDH mutated AML
Gilteritinib MOA/Indications
FLT-3 inhibitor
indicated for patients with relapsed or refractory FLT-3 mutated AML
CC-486 MOA/Indications
oral azacitidine approved at 300 mg daily x 14 days every month
indicated for continued treatment of adult AML patients who achieved first CR or CRi s/p induction chemotherapy who are not able to complete curative therapy
Decitabine-cedazuridine MOA/Indications
hypomethylating agent
indication as an alternative to IV HMA’s for the treatment of adults with MDS or CMML
Molecular subsets
NPM1 without FLT-3/ITD mutations is associated with a more favorable outcome
FLT-3 ITD is associated with a worse prognosis particularly at elevated allele ratios
